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A B S T R A C T
Purpose: Depression is a highly prevalent, relatively underdiagnosed and undertreated comorbid
condition in epilepsy. The purpose of this study was to determine the effect of using a validated self-
reporting depression scale on the ability to detect depression in people with epilepsy receiving care in a
busy clinical setting.
Methods: The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item
questionnaire validated to screen for depression in people with epilepsy. We performed a retrospective
chart review of 192 consecutive patientswho had completed theNDDI-Ewhile receiving care at a seizure
clinic in the largest public hospital in Houston, Texas. For comparison, charts of 192 consecutive patients
receiving care immediately prior to the implementation of the NDDI-E in the same clinic were assessed.
Results: Fifty-ﬁve (28.6%) of patients screened positive for depression with the NDDI-E. They
subsequently received a semi-structured psychiatric interview based on the DSM-IV model and 89%
(n = 49) were conﬁrmed to have major depression. Use of the NDDI-E thus resulted in the detection of
active depression in 25.5% (n = 49) of the patients, whereas only 2.6% (n = 5) of patients in the group not
systematically screened were found to have active depression (p < 0.0001). Thirty-two of the 49 (65%)
patients with depression detected by screening were not previously diagnosed or treated. Multivariate
analysis revealed that a history of depression, seizure frequency, and topiramate use were independent
predictors of depression. Lamotrigine use was protective against depression.
Discussion: Use of the NDDI-E signiﬁcantly improved the ability to detect depression in epilepsy patients
in a busy clinical practice.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Depression is a frequent psychiatric complication encountered
by patients with chronic epilepsy,1–4 with prevalence reported to
be more than 30% in community-based epilepsy populations5 and
between 20% and 55% in tertiary epilepsy centers.6,7 It is a
comorbid condition that adversely affects patients’ health-related
quality of life, independent of seizure frequency.8–12 Depression
not only has a substantial negative effect on subjective health, but
also is a potentially life-threatening illness, contributing to the
signiﬁcantly higher rates of suicidal behavior when compared to* Corresponding author at: One Baylor Plaza, NB 302, Houston, TX 77030, USA.
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epilepsy patients is a difﬁcult undertaking in a busy ambulatory
setting. The diagnosis is often missed in both adults15 and
children.16,17 Approaches to promptly identify clinical depression
can help to improve not only the recognition, but also treatment of
this comorbid disorder. Using self-administered screening tools
can assist in dealing with this problem. The Neurological Disorders
Depression Inventory for Epilepsy (NDDI-E) is a validated screen-
ing tool for depression in patientswith epilepsy that consists of a 6-
item questionnaire (Fig. 1). It can be used to rapidly and reliably
detect depression in a busy clinical setting, as well as differentiate
symptoms of depression from those of medication toxicity and
cognitive effects of epilepsy.18 The present study aims to
determine the effect on recognition of depression by administering
the NDDI-E in a busy urban clinic. In addition, we sought to
determine the risk factors associated with depression in this
patient population.vier Ltd. All rights reserved.
Fig. 1. The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E).
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Ben Taub General Hospital is the largest public hospital in
Houston, Texas, with more than 184,000 clinic visits a year. The
weekly seizure clinicmanages a high volume of patients, visited by
roughly 25 per 3-h session.
The NDDI-E is a 6-item questionnaire that allows for rapid
identiﬁcation ofmajor depression in epilepsy. NDDI-E scores above
15 are considered positive for depression, with speciﬁcity of 90%,
sensitivity of 81%, and positive predictive value of 0.62 for a
diagnosis of major depression based on the mini international
neuropsychiatric interview (MINI).19 NDDI-E total score, indepen-
dent of adverse effects of medication, predicted subjective health
based on the quality of life in epilepsy inventory-89 (QOLIE-89)20
total score. Additional construct validity was supported by
correlations with previously validated instruments. The Spearman
correlation coefﬁcient between the NDDI-E and the Beck Depres-
sion Inventory (BDI)21 was 0.78 and 0.77 between the NDDI-E and
the Center for Epidemiological Studies Depression (CES-D)
scale.22,18
Use of the NDDI-E was approved by the Harris County Hospital
District’s Patient Education Committee in November 2007. The
authors performed a retrospective review of clinic charts of
patients who had received the screening tool from December of
2007 to February of 2008. Patients were instructed to complete the
questionnaire without the assistance of others. A total of 287 adult
patients visited the clinic from December of 2007 to February of
2008. The screening tool was administered to consecutive patients
receiving care in the clinic during that period. Fifty-one were
excluded because they were unable to understand and complete
the NDDI-E without assistance secondary to cognitive limitations
such as mental retardation and/or learning disabilities. Another 44
refused to complete the questionnaire. The remaining 192 patients
visiting the clinic received and completed the NDDI-E as part of
their clinical assessment. NDDI-E scores greater than 15 were
considered positive for depression, as this score was previously
shown to have a speciﬁcity of 90%, sensitivity of 81%, and positive
predictive value of 0.62 for a diagnosis of major depression.18 If a
patient was determined to be depressed based on screening, a
semi-structured psychiatric interview was conducted by the
attending neurologist. The interviews were performed in the
clinic by two of the authors (DEF, SL) who were not blinded to
the NDDI-E scores. The semi-structured interview followed the
DSM-IV criteria for major depression and consisted of questions
pertaining to patients’ mood, anhedonia, ability to concentrate,
fatigue, quality of sleep, changes in appetite, and suicidal ideation
and was based on the Structured Clinical Interview (SCID-1 for
DSM-IV-TR) for current Major Depressive Episode (MDE).23 The
patient was either treated with antidepressant medication,referred to psychiatry, both, or neither. Treatment decisions were
not systematic and were decided by the physician based on
individual patient characteristics and clinical impression. For
instance, if symptoms of depression were temporally related to
initiation or increase in dosage of a particular anti-epileptic drug
(AED), stopping or decreasing the AED was considered. For
comparing rates of depression detection, the charts of 192
consecutive patients receiving care immediately prior to the
implementation of the NDDI-E in the same clinic were assessed.
Prior to implementation of the NDDI-E, patients did not undergo a
psychiatric interview unless they were complaining of symptoms
of depression. Depression was noted if documented in the medical
record and was based on patients’ complaints and physicians’
clinical impression.
Clinical patient variables included age, gender, race/ethnicity,
employment status, marital status, depression history, seizure
frequency,AEDsused,epilepsy type,brainMRI, andEEGﬁndings. For
each variable, descriptive statistics were obtained. Epilepsy
diagnosis was categorized into three groups including: (1) general-
ized epilepsy, (2) localization-related epilepsy, and (3) unknown.
EEG ﬁndings were categorized into four groups: (1) normal, (2)
diffuse slowing, (3) regional slowing, and (4) epileptiform activity.
Four groups divided by race or ethnicity: (1) non-Hispanicwhite, (2)
black, (3) Hispanic, and (4) other. Current marital status into four
groups: (1) single, (2) married, (3) divorced, and (4) widowed. All
other variableswere dichotomized including gender (male/female),
depression history (yes/no), MRI ﬁndings (normal/lesional) and
employment (employed/unemployed).Depressionat the timeof the
clinic visit was inferred from the physicians’ notes in the medical
charts. The strength of association between independent variables
and depression was assessed using Fisher’s exact test and p values
<0.05 were regarded as signiﬁcant. All signiﬁcant variables in the
univariate test were entered in a multiple logistic regression model
to assess potential independent factors and confounders for
depression. Odd ratios (OR), adjusted for age and gender, were
calculated with 95% conﬁdence intervals (CI).
3. Results
No signiﬁcant differences in demographic and clinical char-
acteristics were present between the group receiving the NDDI-E
and the group not receiving the questionnaire. Table 1 provides the
descriptive characteristics of the patients. EEGs were not
performed or EEG reports were not available for 79 patients in
the pre-NDDI-E group and 65 in the NDDI-E group. MRIs were not
performed on 49 in the pre-NDDI-E group or on 29 in the NDDI-E
group. Patients were categorized as having localization-related
epilepsy (LRE) or primary generalized epilepsy (PGE) based on
documentation in clinic charts.
Fifty-ﬁve (28.6%) of patients receiving the NDDI-E were
screened as positive for depression. Forty-nine (89%) of those
that screened positive for depression were conﬁrmed to have
depression following the psychiatric interview, representing
concurrent validity. Thus, detection of active depression occurred
in 25.5% (n = 49) of patients with use of the NDDI-E, whereas only
2.6% (n = 5) of patients in the group not systematically screened
were found to have active depression (p < 0.0001). The mean
NDDI-E score of the patients with false positive results from
screening was 16.7 (median = 16). Thirty-two of the 49 (65%)
patients that had evidence on both the NDDE-I and interview of
depression were not previously diagnosed or treated. Forty-two
percent (n = 23) of the 55 patients in the group with scores of 16 or
greater had a prior diagnosis of depression, four of which (17%)
were not receiving treatment. Sixteen percent (n = 22) of patients
in the group with scores less than 16 were previously diagnosed
with depression, with three (14%) not receiving treatment.
Table 1






Age (mean  S.D.) 41  12 42  13 0.44
Gender n (% male) 91 (48) 85 (44) 0.54
Race/ethnicity n (% Hispanic) 105 (55) 92 (48) 0.18
Depression history n (%) 35 (18) 45 (23) 0.21
Seizure type
LRE n (%) 136 (71) 136 (71) 1.00
PGE n (%) 14 (7) 20 (10) 0.28
EEG
Epileptiform n (%) 28 (15) 30 (16) 0.78
Focal slowing n (%) 18 (9) 23 (12) 0.41
Diffuse slowing n (%) 13 (7) 5 (3) 0.05
Seizure frequency (mean  S.D.) 2  6 3  10 0.24
MRI
Lesion n (%) 60 (31) 70 (36) 0.28
Normal n (%) 59 (31) 75 (40) 0.09
Number of AEDs (mean  S.D.) 1.61  0.83 1.77  0.79 0.06
Employed n (%) 44 (23) 50 (26) 0.41
Marital status
Single n (%) 109 (57) 111 (58) 0.84
Married n (%) 58 (30) 61 (32) 0.74
Divorced n (%) 17 (9) 13 (7) 0.45
S.D., standard deviation; LRE, localization-related epilepsy; PGE, primary general-








Depression history 4.67 2.17–10.02 <0.001
Seizure frequency 1.04 1.01–1.09 0.04
Number of AEDs  3 vs. <3 2.13 0.88–5.16 0.09
Topiramate 2.56 1.05–6.28 0.04
Lamotrigine 0.28 0.09–0.85 0.03
AEDs, anti-epileptic drugs. The bolded values represent values that are statistically
signiﬁcant (p  0.05).
Table 2






Age (mean  S.D.) 42  13 43  13 0.63
Gender n (% male) 60 (44%) 25 (45%) 0.83
Race/ethnicity n (% Hispanic) 69 (50%) 23 (42%) 0.28
Depression history n (%) 22 (16%) 23 (42%) <0.001
Past treatment for depression n (%) 3 (2%) 4 (7%) 0.105
Seizure type
LRE n (%) 95 (69%) 41 (75%) 0.47
PGE n (%) 16 (12%) 4 (7%) 0.44
EEG
Epileptiform n (%) 19 (14%) 11 (20%) 0.29
Focal slowing n (%) 19 (14%) 4 (7%) 0.23
Diffuse slowing n (%) 3 (2%) 2 (4%) 0.63
Seizure frequency (mean  S.D.) 2  6 6  16 0.06
MRI
Lesion n (%) 47 (34%) 23 (42%) 0.33
Normal n (%) 54 (39%) 21 (38%) 0.87
Number of AEDs (mean  S.D.) 1.69  0.75 1.96  0.88 0.05
3 AEDs n (%) 20 (15%) 15 (27%) 0.04
AED
Levetiracetam 55 26 0.37
Topiramate 15 13 0.02
Zonisamide 12 7 0.41
Lamotrigine 27 6 0.14
Carbamazepine 25 15 0.16
Oxcarbazepine 9 6 0.31
Valproic acid 26 11 0.87
Phenobarbital 6 1 0.68
Phenytoin 41 15 0.71
Gabapentin 3 3 0.36
Clonazepam 5 3 0.69
Primidone 2 0 1.00
Employed n (%) 40 (29%) 10 (18%) 0.12
Marital status
Single n (%) 78 (57%) 33 (60%) 0.70
Married n (%) 46 (34%) 15 (27%) 0.40
Divorced n (%) 10 (7%) 3 (5%) 0.76
S.D., standard deviation; LRE, localization-related epilepsy; PGE, primary general-
ized epilepsy; AEDs, anti-epileptic drugs. The bolded values represent values that
are statistically signiﬁcant (p  0.05).
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NDDI-E and interview in the univariate analysis included a history
of depression (p < 0.001), taking three or more AEDs (p = 0.04) and
current use of topiramate (TPM) (p = 0.02). Though seizure
frequency was not signiﬁcantly associated with depression in
the univariate model, when adjusting for the number of AEDs on
the multivariate analysis, it became signiﬁcant (p = 0.04). Factors
independently associated with depression when analyzed with
multiple logistic regression included depression history
(p < 0.001), seizure frequency (p = 0.04), and current TPM use
(p = 0.04). Use of lamotrigine (LTG) was independently protective
against depression (p = 0.03). Tables 2 and 3 show the univariate
and multivariate analyses for patients receiving the NDDI-E.
4. Discussion
This is the ﬁrst study to demonstrate the effectiveness of using a
validated screening tool to identify depression in patients with
epilepsy in a busy clinical setting. Use of the NDDI-E resulted in a
nearly 10-fold improvement in the detection rate. Utilization of the
NDDI-E allowed for an improved recognition of depression, thus
enhancing the quality of the outpatient evaluation in our study, as
mood disorders have a profound negative effect on patients’
subjective health status.2,3,8,9,11,12,24 Addressing symptoms of
depression is an important component of the outpatient evaluation
of patients with epilepsy. Though the NDDI-E is not meant to
replace deﬁnitive means of evaluation such as a structured
psychiatric interview, it can assist in identifying those patients
that may be at risk. This is particularly relevant in a busy
ambulatory setting, where time constraints often restrict the
identiﬁcation of depression.15,25 Our study is unique for its
application of screening for depression in a large urban county
hospital system as there is a known association between low
income and depression alone26 and in patients with epilepsy.5
In our study we found that 25.5% of the patients had current,
major depression, based on the NDDE-I score and conﬁrmation by
the interview. This is similar to prior reports, where rates of active
depression in patients with epilepsy ranged between 17.2% and55%.5,7,13,25,27 Any chronic disorder can predispose a patient to
depression. However, depression is more commonly associated
with epilepsy when directly compared to other chronic conditions,
such as asthma and diabetesmellitus.5,27 There also appears to be a
bidirectional relationship between epilepsy and depression, with
depression reported to be a risk factor for epilepsy.28 A number of
neurobiological factors have been implicated in the association
between the two disorders.29 It is possible that epilepsy and
depression stem from dysfunction within overlapping neuronal
D.E. Friedman et al. / Seizure 18 (2009) 429–433432networks, such as the limbic system. Indeed, patients with
temporal lobe epilepsy tend to have higher rates of mood disorders
than the other forms of epilepsy.1,11
In our cohort, though depression was related to seizure
frequency was statistically signiﬁcant, it was modest, with an
odds ratio (OR) of 1.04 [95% conﬁdence interval (CI), 1.01–1.09].
Nevertheless, a relationship between seizure frequency and
depression exists. The prevalence of depression in epilepsy is
increased in patients with recurrent seizures.13,30,31 Also,
increased relative risk for suicide is associated with a higher
seizure frequency.32 In addition to the possible underlying
biological mechanisms responsible for depression in patients with
frequent seizures, frequent seizures may correlate with patients’
perception of handicap.33 Consequently, this perceived disadvan-
tage continues to increase the burden and stress of a chronic illness
and contributes to symptoms of depression.
A history of depression was related to NDDI-E scores consistent
with depression. In our cohort, it was the strongest independent
predictor for depression [OR 4.67 (CI, 2.14–10.02)]. This highlights
the fact that although patients may carry a diagnosis of comorbid
depression and may even be undergoing treatment, it is never-
theless important to screen these patients as well to assess the
effectiveness of their treatment. In our study, nearly two thirds
(65%) of the patients determined to have depression were not
previously diagnosed or treated. Ensuring that patients are
receiving proper management for depression is just as important
as diagnosing it.
Anti-epileptic drugs alone can contribute to depression. In our
cohort TPMusewas found to be a risk factor for depression and LTG
use protective. Though this data is based on a cross-sectional
assessment and not a randomized trial, it is similar to that found in
previously published reports. TPM’s negative impact on mood in
patients with epilepsy is well known.34–37 Both Kanner et al.34 and
Mula et al.35 indicated that patients with a past psychiatric history
may be at more risk for developing the depressive adverse effects.
Though TPM was independently associated with depression, most
patients were on AED polytherapy, and thus many symptoms
consistent with depression may be attributed to the negative
neurocognitive effects associated with AEDs. LTG consistently
demonstrates positive psychiatric effects on patients.38,39 LTG
cotherapy reverses the depressive side effects of TPM.35 LTG
monotherapy has been shown to improve depressive symptoms in
patients with epilepsy, with a sustained effect for at least 8
months.40 LTG has also been shown to lead to improvement in
mood in patients with primary generalized tonic clonic epilepsy,
independent of its effect on seizure reduction.41
The limitations of the study must be recognized. Certain risk
factors known to be associated with depression in patients with
epilepsy could not be assessed for this study. The receiver
operating characteristic curve (ROC) analysis revealed an area
under the curve of 0.75. This indicates that the variables
measured allowed for fair to good predictability. Other factors
that may have strengthened our analysis include duration of
epilepsy and epilepsy localization. Seizure chronicity is a known
risk factor associated with mood disorders.17,31 Complete data
pertaining to duration of epilepsy was not available in many of
the charts reviewed and was thus not included in the analyses.
Depression is also known to be more common among certain
epilepsy disorders, particularly affecting patients with temporal
lobe epilepsy.1,11 Most patients attending our clinic did not
undergo video-EEG monitoring, and therefore accurate localiza-
tion of their epileptogenic region is not known. We cannot
account for false negatives, as patients with a score less of than
16 on the NDDI-E did not receive the semi-structured
psychiatric interview. However, the results of the NDDI-E and
psychiatric interview revealed concurrent validity, for there wasa high rate of agreement on the results of the screening and
interview. Also, prior to implementing the screening tool, a
systematic psychiatric interview was not performed in the
clinic. Therefore, the comparison of rates of detecting depression
is based on clinical judgment in the pre-NDDI-E group and a
combination of the screening tool and the psychiatric interview
in the NDDI-E group. In an ideal setting, the psychiatric
interview would be performed by a psychiatrist or psychologist.
Nevertheless, the aim of this study was to assess the feasibility
of detecting depression in a busy neurology clinic with an easily
administered validated screening tool.
5. Conclusions
In a busy clinical setting, symptoms of depression are
frequently overlooked or mistaken, as evidenced by our study.
The use of the NDDI-E allowed us to enhance our outpatient
evaluation by improving the identiﬁcation of depression. Both the
prevalence of depression in our study, as well as the risk factors
associated with depression, are similar to previous studies, thus
further supporting the use of the NDDI-E as an accurate tool for
detecting depression in patients with epilepsy. Despite the
limitations in our study, we feel the NDDI-E is useful in a busy
clinical setting and can supplement a productive clinic visit.
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